Nanomedicine in Cancer Clinics: Are We There Yet?

Nayak, Prajna P.; S, Nijil; Vadakkepushpakath, Anoop Narayanan; Badekila, Anjana Kaveri; Kini, Sudarshan

doi:10.1007/s40139-021-00220-6

Cited by 16 publications

(8 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite various approaches to control solid tumor growth, such as surgery, chemotherapy, radiation therapy, and thermotherapy, solid tumors are still the leading cause of death in cancer patients [ 1 ]. The need for better clinical outcomes in patients with cancer has led researchers to reconsider therapeutic strategies.…”

Section: Introductionmentioning

confidence: 99%

An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment

Sharifi

Cho

Ansariesfahani

et al. 2022

Cancers

View full text Add to dashboard Cite

The enhanced permeability and retention (EPR) effect in cancer treatment is one of the key mechanisms that enables drug accumulation at the tumor site. However, despite a plethora of virus/inorganic/organic-based nanocarriers designed to rely on the EPR effect to effectively target tumors, most have failed in the clinic. It seems that the non-compliance of research activities with clinical trials, goals unrelated to the EPR effect, and lack of awareness of the impact of solid tumor structure and interactions on the performance of drug nanocarriers have intensified this dissatisfaction. As such, the asymmetric growth and structural complexity of solid tumors, physicochemical properties of drug nanocarriers, EPR analytical combination tools, and EPR description goals should be considered to improve EPR-based cancer therapeutics. This review provides valuable insights into the limitations of the EPR effect in therapeutic efficacy and reports crucial perspectives on how the EPR effect can be modulated to improve the therapeutic effects of nanomedicine.

show abstract

Section: Introductionmentioning

confidence: 99%

An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment

Sharifi

Cho

Ansariesfahani

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Complexity of chemical synthesis or multistage processes, posing a significant challenge in obtaining consistent physical and chemical properties (size, composition over time) at affordable price, can compromise the successful clinical translation. A better understanding of the tumor type-specific pathophysiology, more connections between research and treatment and NP design based on patient characteristics (biomarker preselection strategies, treatment combinations with a clinical focus on the target disease as it develops in patients) must be implemented to achieve this success (Nayak et al, 2021).…”

Section: Fig 2 Different Types Of Nanoparticles (Adapted From Standardnanocom)mentioning

confidence: 99%

Modulating undruggable targets to overcome cancer therapy resistance

Passirani

Vessières

Regina

et al. 2022

Drug Resistance Updates

View full text Add to dashboard Cite

“…Although cancer nanomedicine celebrates thirty years since its introduction, together with the achievements and progress in cancer treatment area, it still ha serious disadvantages that have to be addressed yet [59] (Figure 3). Since the first observation that macromolecules tend to accumulate in tumor tissue due to fenestrated endothelial of vasculature [60], considered as the "royal gate" in drug delivery field [61], more than dozens of cancer nanoformulations have been approved and introduced as potential treatment approach [62]. Moreover, about~2000 of designed nanoformulations intended to be used for cancer treatment are under clinical trials (search terms: nanoparticle/liposome/micelle/quantum dots/nano) [63,64].…”

Section: Challenges Toward Drug Delivery Systems In Anticancer Therapymentioning

confidence: 99%

Challenges towards Targeted Drug Delivery in Cancer Nanomedicines

2021

View full text Add to dashboard Cite

Despite cancer nanomedicine celebrates already thirty years since its introduction, together with the achievements and progress in cancer treatment area, it still undergoes serious disadvantages that must be addressed. Since the first observation that macromolecules tend to accumulate in tumor tissue due to fenestrated endothelial of vasculature, considered as the “royal gate” in drug delivery field, more than dozens of nanoformulations have been approved and introduced into the practice for cancer treatment. Lipid, polymeric, and hybrid nanocarriers are biocompatible nano-drug delivery systems (NDDs) having suitable physicochemical properties and modulate payload release in response to specific chemical or physical stimuli. Biopharmaceutical properties of NDDs and their efficacy in animal models and humans can significantly affect their impact and perspective in nanomedicine. One of the future directions could be focusing on personalized cancer treatment, considering the heterogeneity and complexity of each patient tumor tissue and the designing of multifunctional targeted NDDs combining synthetic nanomaterials and biological components, like cellular membranes, circulating proteins, RNAi/DNAi, which enforce the efficacy of NDDs and boost their therapeutic effect.

show abstract

Nanomedicine in Cancer Clinics: Are We There Yet?

Cited by 16 publications

References 75 publications

An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment

An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment

Modulating undruggable targets to overcome cancer therapy resistance

Challenges towards Targeted Drug Delivery in Cancer Nanomedicines

Contact Info

Product

Resources

About